Delisting riskPopularity #4,594
IGC Pharma (IGC)
Develops an investigational oral THC-and-melatonin therapy for Alzheimer’s-dementia agitation.
$0.2822
After hours+0.00 (+0.28%)
At close$0.2814(+2.70%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 5.02% | 5.19M shares | |
|---|---|---|---|
| 37 holders · as of Jun 30, 2026 | |||
| Other | 94.98% | 98.19M shares | |
| remainder | |||
103.38M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
37 holders · 5.19M shares · 8 new positions · 14 increased · 6 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 879.4K | 0.85% | −164.0K | Aug 12, 2026 |
| Vanguard Capital Management LLC | 814.9K | 0.79% | +96.5K | Aug 13, 2026 |
| BlackRock, Inc. | 703.8K | 0.68% | 0 | Aug 7, 2026 |
| Advisorshares Investments LLC | 678.5K | 0.66% | +678.5Knew | Aug 11, 2026 |
| Citadel Advisors LLC | 437.3K | 0.42% | +437.3K | Sep 2, 2026 |
| Vanguard Fiduciary Trust Co | 419.4K | 0.41% | +3.5K | Aug 13, 2026 |
| Renaissance Technologies LLC | 286.6K | 0.28% | −197.4K | Aug 13, 2026 |
| State Street Corp | 200.8K | 0.19% | 0 | Aug 7, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.